Ortblad, Katrina F.
Chanda, Michael M.
Musoke, Daniel Kibuuka
Ngabirano, Thomson
Mwale, Magdalene
Nakitende, Aidah
Chongo, Steven
Kamungoma, Nyambe
Kanchele, Catherine
Bärnighausen, Till
Oldenburg, Catherine E. http://orcid.org/0000-0002-0763-399X
Funding for this research was provided by:
International Initiative for Impact Evaluation
National Institute of Allergy and Infectious Disease (T32-AI007535)
National Institute of Mental Health (R01-MH110296, R01-MH113572)
Alexander von Humboldt Foundation
Wellcome Trust
European Commission
Clinton Health Access Initiative
NICHD (R01-HD084233)
NIAID (R01-AI124389, R01-AI112339)
Forgarty International Center (D43-TW009775)
National Institute on Drug Abuse (T32-DA013911)
NIMH (R25-MH083620)
Article History
Received: 3 July 2018
Accepted: 26 September 2018
First Online: 4 October 2018
Ethics approval and consent to participate
: Both studies were reviewed and approved by the Institutional Review Board at the Harvard T.H. Chan School of Public Health. The Zambia study was reviewed and approved by the Institutional Review Board at ERES Converge (Lusaka, Zambia) and the Uganda study was reviewed and approved by the Institutional Review Board at Mildmay (Kampala, Uganda). Written informed consent was obtained from all participants.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.